Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
about
Role of BRCA2 mutation status on overall survival among breast cancer patients from SardiniaTiming of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON studyWomen's constructions of the 'right time' to consider decisions about risk-reducing mastectomy and risk-reducing oophorectomy.Group medical visits in the follow-up of women with a BRCA mutation: design of a randomized controlled trial.The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy.Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers.Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysisBRCA mutation testing in determining breast cancer therapy.Predictors for contralateral prophylactic mastectomy in breast cancer patients.Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillanceLong-term psychosocial outcomes of BRCA1/BRCA2 testing: differences across affected status and risk-reducing surgery choice.Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled TrialsMastectomy and contralateral prophylactic mastectomy rates: an institutional review.International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriersImpact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance)Role of Breast Surgery in BRCA Mutation Carriers.Preserving the self: the process of decision making about hereditary breast cancer and ovarian cancer risk reduction.Intentions for bilateral mastectomy among newly diagnosed breast cancer patientsTamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.Impact of genetic risk assessment on nutrition-related lifestyle behavioursGenetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda.Attitudes to contralateral risk reducing mastectomy among breast and plastic surgeons in England.Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial.Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.Long-term satisfaction and quality of life following risk reducing surgery in BRCA1/2 mutation carriers.Trends in the local treatment of breast cancer: should we be worried?United States trends in the surgical treatment of primary breast cancer.Options in breast cancer local therapy: who gets what?Managing the breast in patients who test positive for hereditary breast cancer.Sentinel lymph node biopsy during prophylactic mastectomy: is there a role?Opportunities and challenges of next-generation DNA sequencing for breast units.Comparison of risk management strategies between women testing positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations.Prophylactic mastectomy: who needs it, when and why.The role of body size and physical activity on the risk of breast cancer in BRCA mutation carriers.Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.Celebrity Health Announcements and Online Health Information Seeking: An Analysis of Angelina Jolie's Preventative Health Decision.Assessing, Counseling, and Treating Patients at High Risk for Breast Cancer.Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery.
P2860
Q30858718-C6B4882A-A9B6-477B-B696-BA97B9C66EDFQ30896495-B32A15D2-C544-4197-A614-F7FCA57C459AQ33650424-6C5EEF1E-B538-4A03-AC42-19E39282356BQ34001845-792DD242-9C4C-4465-88C2-5306CC7F6E0FQ34481713-BD200AE4-E467-4123-94CE-E312CDCD5408Q35021170-9A0791A9-3ADD-47CD-BF41-73C961E169EDQ35163789-41CDBE90-1FF3-43CE-ADB2-981BE16D5199Q35192288-4C9DA715-0459-4C04-AF6B-BF15568AEEE7Q35619225-C682BFBA-9CB2-442A-9EF0-DD8E8422719CQ35741001-0FB8AD05-729B-4A0B-8FC2-7172F45EED66Q35777905-959E52F0-B80C-4F2D-BC21-5E073307F6AFQ35815469-F6CD9AE5-A276-4729-86E3-7E5F54F91E55Q35881780-E62D6125-F3CD-4C8F-A704-768EB2C51C40Q36026667-2F7ED14B-5FB1-4AF6-8705-191DE01941CAQ36168564-8F45FA31-9D88-4962-AC9C-F554B3EE9D79Q36455979-D331DA9B-4084-41EE-8167-A0918268ED32Q36457900-110ADEEF-44EC-4B9D-B47F-1FBB2F7C874EQ36936080-EF7D7761-F8D7-46A9-B613-6B946D020DB3Q36943042-FE2B0723-82C3-4632-81D6-4FAF7ABE7C94Q37122297-ACFBC432-7A2C-4722-889B-9DAE6A211165Q37130341-7A0ED71F-E2C8-4047-B160-93728E740B0EQ37131303-CEBD90DE-078E-435F-AB29-4B29FB68BE48Q37556568-187D85FA-8509-4C39-99DB-AA4A6DCB426DQ37578483-BE05899F-3487-4C70-A9D0-34146CD3E877Q37594381-F9FC29DD-2827-432E-B2BC-C618FCF444C9Q37669779-D86FBD46-96EC-4965-A8A9-CA5E984B9691Q37688802-37FAB572-E35E-40ED-9E1F-193DE86BB6DFQ37845309-4CAAD8B5-CA7A-44E7-99DC-A412E82B4029Q37986554-CF04DEE0-FC94-4BF5-95F7-4062EF0E722EQ37989842-D6E3172C-0F91-40AD-83C8-98F710217EACQ37991240-F4CDD26E-352D-4F70-8587-BA8A4070A8F2Q38188901-9180C96B-378B-494A-BCD0-38F9C6BAAAE6Q38200002-AF5739F8-4016-4183-96D5-AE5D214D76EEQ38213995-A87D5F09-D7ED-4212-B899-42FA347D6709Q38223259-98B82ED2-61F5-430A-A9B9-2F47C874FF08Q38314472-AE235BA8-C929-4CAF-BD75-50D26C38BBC6Q38759417-21071A1F-DD4B-4285-B4D1-861E8D282DB2Q39218266-422C9DCA-E298-4704-BFDD-49C878D6AFDFQ39612960-7A02F5F7-A993-4E86-A90E-36E238ACC3B7Q40048374-45D7A8BD-09ED-4CB5-885E-247426FC1B95
P2860
Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Predictors of contralateral pr ...... t Cancer Clinical Study Group.
@en
Predictors of contralateral pr ...... t Cancer Clinical Study Group.
@nl
type
label
Predictors of contralateral pr ...... t Cancer Clinical Study Group.
@en
Predictors of contralateral pr ...... t Cancer Clinical Study Group.
@nl
prefLabel
Predictors of contralateral pr ...... t Cancer Clinical Study Group.
@en
Predictors of contralateral pr ...... t Cancer Clinical Study Group.
@nl
P2093
P50
P356
P1476
Predictors of contralateral pr ...... t Cancer Clinical Study Group.
@en
P2093
Charmaine Kim-Sing
Eitan Friedman
Henry Lynch
Hereditary Breast Cancer Clinical Study Group
Jacek Gronwald
Kelly A Metcalfe
Nadine Tung
Parviz Ghadirian
Peter Ainsworth
P304
P356
10.1200/JCO.2007.12.6078
P407
P50
P577
2008-01-14T00:00:00Z